ASH 2023 | CNTY-101 in follicular lymphoma: a case study from the ELiPSE-1 trial
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, presents a case study of a patient with relapsed/refractory (R/R) follicular lymphoma (FL) treated with CNTY-101, an iPSC-derived allogeneic CD19 targeting CAR-NK product, in the Phase I ELiPSE-1 trial (NCT05336409). The patient responded to treatment after one cycle, with evidence of immune activation and increased T-cell number in the lymph nodes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So we are presenting translational data from the CNTY-101 Phase I trial. So we presented a case report of a patient, the first patient enrolled in the trial, and really looking at correlative markers to give us some early insights into how this therapy might work. And what we showed was this patient had an early response, so after one cycle of treatment, had a response...
So we are presenting translational data from the CNTY-101 Phase I trial. So we presented a case report of a patient, the first patient enrolled in the trial, and really looking at correlative markers to give us some early insights into how this therapy might work. And what we showed was this patient had an early response, so after one cycle of treatment, had a response. And when we looked at various levels of immune activation, including in a lymph node biopsy from the patient, we could see an increase in T-cell numbers, activation of different parts of the immune system, including interferon gamma signaling. So this all suggests that these NK-cells are quite capable of stimulating an immune response in patients with lymphomas.
Read more...
Disclosures
Consultancy: Pharmacyclics/Janssen, TG Therapeutics, AstraZeneca, Caribou Biosciences, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Epizyme, ADC Therapeutics, BeiGene, Morphosys, Bristol Myers Squibb, Merck, Abbvie; Research Funding: Pharmacyclics/Janssen, Sunesis Pharmaceuticals, Nurix, AstraZeneca, Fate Therapeutics, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Curis, Inc, Epizyme, CRISPR Therapeutics, Bristol Myers Squibb, Merck, Adaptive Biotechnologies; Speakers Bureau: TG Therapeutics, AstraZeneca, Kite, Bristol Myers Squibb.
